SAN ANTONIO (EGMN) – For women with early breast cancer, a combination regimen of docetaxel and cyclophosphamide is well tolerated and provides a significant long-term disease-free and overall survival advantage over a regimen of doxorubicin/cyclophosphamide, according to new data from a phase III trial involving more than 1,000 women.The docetaxel combination was equally effective for patients with human growth factor receptor 2 (HER2)–positive and –negative disease, and should be considered as...